Cardiovascular Medicine Section and Myocardial Biology Unit Boston University School of Medicine Boston MA.
J Am Heart Assoc. 2021 Jul 6;10(13):e019995. doi: 10.1161/JAHA.120.019995. Epub 2021 Jun 25.
Background Inhibitors of the sodium-glucose linked transporter 2 improve cardiovascular outcomes in patients with or without type 2 diabetes mellitus, but the effects on cardiac energetics and mitochondrial function are unknown. We assessed the effects of sodium-glucose linked transporter 2 inhibition on mitochondrial function, high-energy phosphates, and genes encoding mitochondrial proteins in hearts of mice with and without diet-induced diabetic cardiomyopathy. Methods and Results Mice fed a control diet or a high-fat, high-sucrose diet received ertugliflozin mixed with the diet (0.5 mg/g of diet) for 4 months. Isolated mitochondria were assessed for functional capacity. High-energy phosphates were assessed by P nuclear magnetic resonance spectroscopy concurrently with contractile performance in isolated beating hearts. The high-fat, high-sucrose diet caused myocardial hypertrophy, diastolic dysfunction, mitochondrial dysfunction, and impaired energetic response, all of which were prevented by ertugliflozin. With both diets, ertugliflozin caused supernormalization of contractile reserve, as measured by rate×pressure product at high work demand. Likewise, the myocardial gene sets most enriched by ertugliflozin were for oxidative phosphorylation and fatty acid metabolism, both of which were enriched independent of diet. Conclusions Ertugliflozin not only prevented high-fat, high-sucrose-induced pathological cardiac remodeling, but improved contractile reserve and induced the expression of oxidative phosphorylation and fatty acid metabolism gene sets independent of diabetic status. These effects of sodium-glucose linked transporter 2 inhibition on cardiac energetics and metabolism may contribute to improved structure and function in cardiac diseases associated with mitochondrial dysfunction, such as heart failure.
背景 钠-葡萄糖协同转运蛋白 2 抑制剂可改善伴有或不伴有 2 型糖尿病的患者的心血管结局,但对心肌能量代谢和线粒体功能的影响尚不清楚。我们评估了钠-葡萄糖协同转运蛋白 2 抑制剂对伴有和不伴有饮食诱导的糖尿病心肌病的小鼠心脏中线粒体功能、高能磷酸化合物以及编码线粒体蛋白的基因的影响。
方法和结果 给予对照饮食或高脂肪、高蔗糖饮食的小鼠用饮食混合(0.5mg/g 饮食)给予恩格列净 4 个月。评估分离的线粒体的功能能力。通过 P 磁共振谱同时评估高能磷酸化合物和分离搏动心脏的收缩性能。高脂肪、高蔗糖饮食导致心肌肥大、舒张功能障碍、线粒体功能障碍和能量代谢反应受损,所有这些都可被恩格列净预防。用两种饮食,恩格列净导致收缩储备的超正常化,如高工作需求时的速率×压力乘积来衡量。同样,恩格列净最富集的心肌基因集是氧化磷酸化和脂肪酸代谢,这两者的富集都独立于饮食。
结论 恩格列净不仅可预防高脂肪、高蔗糖引起的病理性心脏重构,还可改善收缩储备,并诱导氧化磷酸化和脂肪酸代谢基因集的表达,而与糖尿病状态无关。钠-葡萄糖协同转运蛋白 2 抑制剂对心脏能量代谢的这些影响可能有助于改善与线粒体功能障碍相关的心脏疾病(如心力衰竭)的结构和功能。